Table 2.
Mortality Risk by Mediastinal Lymph Node Characteristics in Patients with Interstitial Lung Disease
| Characteristic | Primary Cohort: UCHICAGO (n = 1,094) |
Replication Cohort 1: INSPIRE (n = 228) |
Replication Cohort 2: NONTERT (n = 250) |
Replication Cohort 3: UCDAVIS (n = 215) |
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Univariate Cox regression | ||||||||
| MLN* ≥10 mm | 1.91 (1.46–2.50) | <0.001 | 1.96 (1.00–3.81) | 0.048 | 1.79 (1.13–2 . 84) | 0.013 | 3.78 (1.62–8.82) | 0.002 |
| PT MLN station* (stations 1–7) | 1.92 (1.46–2.52) | <0.001 | 1.82 (0.92–3.59) | 0.085 | 1.79 (1.13–2.84) | 0.013 | 3.53 (1.50–8.33) | 0.004 |
| LZ MLN station* (stations 8 and 9) | 2.57 (1.42–4.64) | 0.002 | 4.64 (1.32–16.4) | 0.017 | — | — | 5.27 (1.09–25.48) | 0.039 |
| MLN count* | 1.25 (1.17–1.33) | <0.001 | 1.33 (0.96–1.83) | 0.083 | 1.21 (1.00–1.45) | 0.046 | 1.51 (1.16–1.97) | 0.002 |
| Multivariable Cox regression† | ||||||||
| MLN* ≥10 mm | 1.53 (1.12–2.10) | 0.008 | 2.50 (1.01–6.22) | 0.048 | 2.12 (1. 09–4.13) | 0.028 | 3.54 (1.41–8.93) | 0.007 |
| PT MLN station* (stations 1–7) | 1.52 (1.11–2.09) | 0.010 | 2.15 (0.85–5.49) | 0.132 | 2.12 (1.09–4.13) | 0.028 | 3.51 (1.38–8.88) | 0.008 |
| LZ MLN station* (stations 8 and 9) | 2.10 (1.01–4.35 | 0.046 | 6.16 (1.53–24.7) | 0.010 | — | — | 3.50 (0.64–19.03) | 0.147 |
| MLN count* | 1.12 (1.04–1.20) | 0.003 | 1.34 (0.91–1.97) | 0.138 | 1.66 (0.86–3.23) | 0.132 | 1.52 (1.13–2.04) | 0.006 |
Definition of abbreviations: CI = confidence interval; HR = hazard ratio; ILD = interstitial lung disease; INSPIRE = Effect of Interferon Gamma-1b on Survival in Patients with Idiopathic Pulmonary Fibrosis Trial; LZ = lower zone; MLN = mediastinal lymph node; NONTERT = nontertiary hospital cohort with adjudicated multidisciplinary interstitial lung disease diagnosis; PT = paratracheal; UCDAVIS = University of California Davis; UCHICAGO = University of Chicago.
In the INSPIRE cohort, 228 patients had high-resolution computed tomography of acceptable quality available for mediastinal evaluation.
Compared to patients without enlarged MLN (i.e., MLN <10 mm).
Adjusted for sex, age, FVC, DlCO, ILD subtype, tobacco pack-years, body mass index, immunosuppressive therapy, antifibrotic therapy, and hospital center.